VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility

by NASDAQ Market News August 30, 2021

NASDAQ Market News
Click here to email author

Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

New Study Provides Insights into the Biocompatibility and Durability of the UroLift® System in Improving Benign Prostatic Hyperplasia Symptoms

Ads